art levinson for managing to keep DNA independent. If the credit crisis gets worse or continues for awhile, he may get positive adjuvant CRC data with avastin and the offer will have to go up substantially.
How about Howard Robin of Sirna Therapeutics (now CEO of NKTR)? Robin transformed Sirna from the carcass of a failed technology company to a $1.1B buyout by MRK in less than six years.
Other worthy candidates: John Maraganore of ALNY, John Martin of GILD, and David Pyott of AGN.
Market Data 
Markets 
AI
